Phase 1 Primary Central Nervous System Lymphoma Clinical Trials
12 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–12 of 12 trials
Recruiting
Phase 1
Autologous CD19-CD20-NKG2D-nsBicephali CAR-T for Relapsed/Refractory Central Nervous System Lymphoma
Relapsed/Refractory Primary Central Nervous System LymphomaRelapsed/Refractory Central Nervous System LymphomaRelapsed/Refractory Secondary Central Nervous System Lymphoma
Beijing Boren Hospital30 enrolled1 locationNCT07555561
Recruiting
Phase 1Phase 2
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078
Recruiting
Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
Primary Central Nervous System Lymphoma
National Cancer Institute (NCI)93 enrolled1 locationNCT02203526
Recruiting
Phase 1
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
LymphomaPrimary Central Nervous System Lymphoma
Dana-Farber Cancer Institute15 enrolled2 locationsNCT06475235
Recruiting
Phase 1Phase 2
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Refractory CancerPrimary Central Nervous System LymphomaRecurrent Cancer+1 more
Dana-Farber Cancer Institute37 enrolled4 locationsNCT04421560
Recruiting
Phase 1
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Primary Central Nervous System LymphomaCentral Nervous System LymphomaSecondary Central Nervous System Lymphoma+4 more
Memorial Sloan Kettering Cancer Center26 enrolled8 locationsNCT07082868
Recruiting
Phase 1
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
Primary Central Nervous System LymphomaSecondary Central Nervous System Lymphoma
City of Hope Medical Center20 enrolled1 locationNCT06922604
Recruiting
Phase 1
A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants
Primary Central Nervous System Lymphoma (PCNSL)
Ono Pharmaceutical Co. Ltd32 enrolled2 locationsNCT07198087
Recruiting
Phase 1
Q702 for the Treatment of Patients With Hematologic Malignancies
Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more
Mayo Clinic46 enrolled2 locationsNCT06712810
Recruiting
Phase 1Phase 2
A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
Relapsed/Refractory Primary Central Nervous System Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University38 enrolled1 locationNCT06556199
Recruiting
Phase 1Phase 2
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
Primary Central Nervous System LymphomaSecondary Central Nervous System LymphomaCNS Lymphoma
James Rubenstein35 enrolled1 locationNCT05351593
Not Yet Recruiting
Phase 1
ALLG NHL41: A phase I clinical trial investigating the combination of chimeric antigen receptor-T cell (CAR-T) cell therapy with Zanubrutinib bridging and subsequent Zanubrutinib and Tislelizumab consolidation in patients with relapsed/refractory Primary Central Nervous System Lymphoma (PCNSL).
Primary Central Nervous System Lymphoma (PCNSL)
Australasian Leukaemia and Lymphoma Group (ALLG)25 enrolled1 locationACTRN12625000001493